Compare AXGN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | MESO |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Australia |
| Employees | N/A | 108 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2013 | 2005 |
| Metric | AXGN | MESO |
|---|---|---|
| Price | $48.18 | $17.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $42.33 | N/A |
| AVG Volume (30 Days) | ★ 776.6K | 179.9K |
| Earning Date | 04-28-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $225,208,000.00 | N/A |
| Revenue This Year | $20.57 | $629.74 |
| Revenue Next Year | $16.68 | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.21 | N/A |
| 52 Week Low | $15.27 | $13.05 |
| 52 Week High | $52.91 | $21.50 |
| Indicator | AXGN | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 53.65 |
| Support Level | $29.48 | $16.56 |
| Resistance Level | $52.91 | $17.33 |
| Average True Range (ATR) | 2.30 | 0.47 |
| MACD | -0.40 | -0.04 |
| Stochastic Oscillator | 30.89 | 32.80 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.